NICE recommends Humira as the first approved treatment for skin condition hidradenitis suppurativa

NICE has recommended adalimumab (Humira) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy, as per the marketing authorisation for adalimumab. Following this recommendation suitable patients in England and Wales should be able to access adalimumab on the NHS. Also known as acne inversa, HS is a painful, chronic, systemic, debilitating lifetime skin disease which has no cure. An estimated 977,900 individuals across the UK suffer from the condition. HS causes recurrent, painful abscesses and nodules (boil-like lumps) in specific areas of the body including the underarm and